Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Petros Pharmaceuticals, Inc.PTPI · Entity 8730 | President, Timm Medical | May 11, 2021 | August 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Petros Pharmaceuticals, Inc.
Report date May 11, 2021 · Filed August 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.21 · Expires 2031-05-11 | Direct | 75,000 |
Reported balance
After 2021-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-11 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares of common stock underlying the options vested 30% on the date of grant, 30% shall vest upon the first annual anniversary of the date of grant and 40% shall vest upon the second annual anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the options vested 30% on the date of grant, 30% shall vest upon the first annual anniversary of the date of grant and 40% shall vest upon the second annual anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2021 Filed Aug 5, 2021 22:01 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001567619-21-014525 · doc1.xml · derivative · entry 1 Gesek Andrew · CIK 0001833990 · President, Timm Medical 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-05-11 F1 · derivative.exercise_date: The shares of common stock underlying the options vested 30% on the date of grant, 30% shall vest upon the first annual anniversary of the date of grant and 40% shall vest upon the second annual anniversary of the date of grant. Read SEC document |
| December 01, 2020 Filed Dec 4, 2020 02:59 UTC | Petros Pharmaceuticals, Inc. PTPI · Entity 8730 | GrantCommon Stock, par value $0.0001 per share | 97 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020632 · doc1.xml · nonDerivative · entry 1 Gesek Andrew · CIK 0001833990 · President, Timm Medical 10b5-1 filing: Not disclosed Ownership: Indirect · By Metuchen Therapeutics, LLC Disclosed balance after: 97 F1 · price: Received in exchange for 196.43 units of Metuchen Pharmaceuticals, LLC ("Metuchen") in connection with the merger (the "Merger") of Metuchen into Petros Pharmaceuticals, Inc. ("Petros"). Mr. Gesek's holding of units of Metuchen was on a look-through basis based on proportionate ownership of Metuchen Therapeutics, LLC, which owned 550,000 units of Metuchen. On the effective date of the Merger, the closing price of Petros was $3.99 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.